LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 ...
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today ...
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no ...
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), ...
AstraZeneca has scrapped an asthma program after the FLAP inhibitor flopped in a phase 2 trial. The U.K.-based Big Pharma had been evaluating the therapy, called atuliflapon, in a midstage study of ...
Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopenia (HIT)PONTE VEDRA, Fla., May 07, 2026 (GLOBE ...
Dublin, May 11, 2026 (GLOBE NEWSWIRE)-- The "Gastric Cancer - Global Clinical Trials Review, 2026" has been added to ResearchAndMarkets.com's offering. This comprehensive report presents top-line data ...
Stocktwits on MSN
CVKD stock retail sentiment peaks after FDA clears phase 3 path for blood clot drug
Cadrenal is now planning a randomized, placebo-controlled study alongside standard anticoagulants. ・The company's Phase 2 data showed over a 25% reduction in clotting, though the trial missed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results